Pantheon, LGT back early-stage biotech restructuring

The deal involving Medicxi was based around six assets and completed at a premium to NAV, co-founder Francesco De Rubertis told Secondaries Investor.

SECONDARIES INVESTOR

Register to unlock this content

• Daily global secondaries market news and intelligence
• Curated insights to keep you ahead of GP-led and LP-led secondaries
• Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
• Access to proprietary research and reports
• Selected fund performance and investor activity data

Register nowFind out more

DealsInvestorsManagersEuropeFeaturedGP-LedsLegal & Regulation